Difference between revisions of "Dactinomycin (Cosmegen)"
Jump to navigation
Jump to search
Line 24: | Line 24: | ||
* 12/10/1964: Initial FDA approval | * 12/10/1964: Initial FDA approval | ||
* 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Wilms tumor]]. ''(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)'' | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Wilms tumor]]. ''(Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)'' | ||
− | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of childhood [[rhabdomyosarcoma]]. | + | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of childhood [[rhabdomyosarcoma]]. ''(Based on IRS-III)'' |
− | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Ewing sarcoma]]. | + | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Ewing sarcoma]]. ''(Based on ET-1)'' |
− | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of metastatic, nonseminomatous [[testicular cancer]]. | + | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of metastatic, nonseminomatous [[testicular cancer]]. ''(Based on Bosl et al. 1986 & Vugrin et al. 1981)'' |
− | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of [[gestational trophoblastic neoplasia]]. | + | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of [[gestational trophoblastic neoplasia]]. ''(Based on Osathanondh et al. 1975)'' |
* 3/13/2009: (earliest label available on Drugs@FDA) Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. | * 3/13/2009: (earliest label available on Drugs@FDA) Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. | ||
Revision as of 20:36, 4 June 2022
General information
Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Dactinomycin (Cosmegen) patient drug information (Chemocare)[3]
- Dactinomycin (Cosmegen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/10/1964: Initial FDA approval
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of Wilms tumor. (Based on NWTS-1, NWTS-2, NWTS-3, NWTS-4)
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of childhood rhabdomyosarcoma. (Based on IRS-III)
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of Ewing sarcoma. (Based on ET-1)
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of metastatic, nonseminomatous testicular cancer. (Based on Bosl et al. 1986 & Vugrin et al. 1981)
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. (Based on Osathanondh et al. 1975)
- 3/13/2009: (earliest label available on Drugs@FDA) Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
Also known as
- Generic names: AC-DE, actinomycin D
- Brand names: Cosmegen, Dacmozen, Lyovac
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Antitumor antibiotics
- Human DNA synthesis inhibitors
- Endometrial cancer medications
- Ewing sarcoma medications
- Gestational trophoblastic neoplasia medications
- Rhabdomyosarcoma medications
- Wilms tumor medications
- Osteosarcoma medications (historic)
- Testicular cancer medications (historic)
- FDA approved in 1964
- WHO Essential Cancer Medicine